Others titles
- medDRA System Organ Class Database
- PROTECT Adverse Drug Reactions Database
- Adverse Drug Effects Database
Keywords
- Adverse Drug Reactions
- Meddra Preferred Term List
- Preferred Terms
- System Organ Class List
- Meddra Terms Listing
- Adverse Event
- Adverse Effects
Adverse Reaction with Preferred Term and System Organ Class Codes

The database includes adverse drug reaction that is associated with the product and substance with MedDRA Preferred Term (PT), PT codes, System Organ Class (SOC) codes etc. This structured database can be used to know whether or not adverse reactions are recorded in the European Summary of Product Characteristics (SPC).
Get The Data
- The data in CSV format DOWNLOAD
- Metadata in Human Readable format (PDF) DOWNLOAD
- Metadata in Machine Readable format (JSON) DOWNLOAD
- Research
Non-Commercial,
Share-Alike,
Attribution Free Forever
- Commercial
Commercial Use,
Remix & Adapt,
White Label Buy Subscription
Description
The Protect Adverse Drug and Product Reaction Database lists adverse drug reactions in 4.8 of the Summary of Product Characteristics (SPPC) of the EU authorized medicinal products based on centralized procedure. The database follows MedDRA terminology. MedDRA Preferred Terms (PT) are used to facilitate the accuracy of ADR descriptions.
MedDRA Preferred Terms (PT) are used to map terms of the SPC. When they are used in the SPC to add precision in the description of the ADR, Low Level Terms (LLTs) are also coded. PTs and LLTs are linked to a primary System Organ Class (SOC). The dataset also includes information on gender, causality, frequency, class warning and source of information for ADRs for which additional information is provided in the SPC.
About this Dataset
Data Info
Date Created | 2015-06-30 |
---|---|
Last Modified | 2017-07-04 |
Version | 2016-06-30 |
Update Frequency |
Annual |
Temporal Coverage |
N/A |
Spatial Coverage |
N/A |
Source | John Snow Labs; European Medicines Agency (EMA) and PROTECT Partners; |
Source License URL | |
Source License Requirements |
N/A |
Source Citation |
N/A |
Keywords | Adverse Drug Reactions, Meddra Preferred Term List, Preferred Terms, System Organ Class List, Meddra Terms Listing, Adverse Event, Adverse Effects |
Other Titles | medDRA System Organ Class Database, PROTECT Adverse Drug Reactions Database, Adverse Drug Effects Database |
Data Fields
Name | Description | Type | Constraints |
---|---|---|---|
Medicinal_Product | Brandname of the centrally authorized product | string | required : 1 |
Active_Substance | Active substance in the medicinal product | string | - |
Date_Of_Most_Recent_SPC | Date of the most recent Summary of Product Characteristic. Whichever date is most recent: date of first authorization or date of the latest version of the SPC found on the European Commission website http://ec.europa.eu/health/documents/communityregister/html/brand_full.html. | date | - |
Remarks_On_Date_Of_Most_Recent_SPC | "Opinion" is mentioned as a remark against the date regarding if the date of the most recent Summary of Product Characteristic is opinionated. Date of most recent SPC can be found on the European Commission website http://ec.europa.eu/health/documents/communityregister/html/brand_full.html | string | - |
Adverse_Drug_Reaction_Term | Adverse Drug Reaction term as it appears in the SPC | string | - |
SOC_If_No_Matching_PT | System Organ Class | string | - |
HLGT_If_No_Matching_PT | High Level Group Term | string | - |
HLT_If_No_Matching_PT | High Level Term | string | - |
LLT_If_No_Matching_PT | Low Level Term | string | - |
MedDRA_PT_Text | MedDRA Preferred Term | string | - |
MedDRA_PT_Code | Preferred Term Code | number | level : Nominal |
MedDRA_SOC_Code | System Organ Class Code | number | level : Nominal |
Age_Group | Age group, if ADR is mentioned to be related to age group | string | - |
Gender | Gender if ADR is mentioned to be related to gender | string | - |
Causality | Coding of any additional wording existing in the SPC and providing additional information on the strength of causal association. If a product is made of more than one substance, and an ADR has occurred with one substance only, the ADR has been listed with a causality of 0 (established ADR) and a comment has been added in the Comment field to indicate which substance has caused the ADR | string | - |
Frequency | The frequency category mentioned in the Table of ADRs. The comment “CF” (conflicting frequencies) has been added in the Comment field when an ADR has been observed with two conflicting frequencies for the same product. This could happen in the following cases: - when several clinical trials with different results (and sometimes different indications) are reported in the SPC; - when ADRs are listed for each individual component of a product. If a frequency is described with a percentage rather than with a standard wording (i.e. unknown, very rare, rare, uncommon, common or very common), the category is “0” as figures have not been interpreted. | string | - |
Is_Class_Warning | Does the SPC (section 4.8) indicate that the adverse reaction is observed in the same class of drug or is pharmacological class effect (or is there a similar statement)? | boolean | - |
Is_Clinical_Trial | Is the adverse reaction listed in a table presenting results of clinical trials, or is it mentioned in the context of clinical trials? | boolean | - |
Is_Post_Marketing_Surveillance | Post-marketing surveillance. Is the adverse reaction listed in a table presenting data from post-marketing surveillance, or is it mentioned in the context of post-marketing surveillance? If the SPC states that the ADRs have been observed from spontaneous reporting and in clinical trials without specifying which ADRs have been observed in which, then “false” has been entered in both fields “Clinical Trial” and “Post-marketing surveillance”. | boolean | - |
Comment | This field has been used to include any additional useful information like ADRs occurring in specific indications or with concomitant drugs, to explain the causality assessment, or to indicate with which individual drug component an ADR has been observed. | string | - |
Data Preview
Medicinal_Product | Active_Substance | Date_Of_Most_Recent_SPC | Remarks_On_Date_Of_Most_Recent_SPC | Adverse_Drug_Reaction_Term | SOC_If_No_Matching_PT | HLGT_If_No_Matching_PT | HLT_If_No_Matching_PT | LLT_If_No_Matching_PT | MedDRA_PT_Text | MedDRA_PT_Code | MedDRA_SOC_Code | Age_Group | Gender | Causality | Frequency | Is_Class_Warning | Is_Clinical_Trial | Is_Post_Marketing_Surveillance | Comment |
Foclivia | A/VIETNAM/1194/2004 (H5N1) | 2015-05-27 | PAIN | PAIN | 10033371 | 10018065 | ADR occurs in children only | Very common | true | false | in children and adolescents aged 3-17 years | ||||||||
Foclivia | A/VIETNAM/1194/2004 (H5N1) | 2015-05-27 | INDURATION | INDURATION | 10060708 | 10018065 | ADR occurs in children only | Very common | true | false | in children aged 6 months to 17 years | ||||||||
Foclivia | A/VIETNAM/1194/2004 (H5N1) | 2015-05-27 | ECCHYMOSIS | ECCHYMOSIS | 10014080 | 10040785 | ADR occurs in children only | Very common | true | false | in infants and toddlers 6 to 35 months of age | ||||||||
Perjeta | PERTUZUMAB | 2015-09-18 | CHILLS | CHILLS | 10008531 | 10018065 | Age category not specified or unclear | Not specified, unclear or both genders | Unassessable or unclear | Common | false | true | false | ||||||
Perjeta | PERTUZUMAB | 2015-09-18 | PAIN | PAIN | 10033371 | 10018065 | Age category not specified or unclear | Not specified, unclear or both genders | Unassessable or unclear | Very common | false | true | false | ||||||
Perjeta | PERTUZUMAB | 2015-09-18 | RASH | RASH | 10037844 | 10040785 | Age category not specified or unclear | Not specified, unclear or both genders | Unassessable or unclear | Very common | false | true | false | ||||||
Perjeta | PERTUZUMAB | 2015-09-18 | COUGH | COUGH | 10011224 | 10038738 | Age category not specified or unclear | Not specified, unclear or both genders | Unassessable or unclear | Very common | false | true | false | ||||||
Perjeta | PERTUZUMAB | 2015-09-18 | DRY SKIN | DRY SKIN | 10013786 | 10040785 | Age category not specified or unclear | Not specified, unclear or both genders | Unassessable or unclear | Common | false | true | false | ||||||
Perjeta | PERTUZUMAB | 2015-09-18 | DYSPNOEA | DYSPNOEA | 10013968 | 10038738 | Age category not specified or unclear | Not specified, unclear or both genders | Unassessable or unclear | Common | false | true | false | ||||||
Perjeta | PERTUZUMAB | 2015-09-18 | PRURITUS | PRURITUS | 10037087 | 10040785 | Age category not specified or unclear | Not specified, unclear or both genders | Unassessable or unclear | Common | false | true | false |